Brought to you by 
Luminex pays $77mm for Nanosphere
08 Sep 2020
Executive Summary
Luminex Corp. is paying $77mm ($1.70 per share; a 63% premium) in cash to acquire molecular diagnostics firm Nanosphere Inc. Luminex also agreed to retire $25mm of Nanosphere debt.
Deal Industry
- In Vitro Diagnostics
- Research, Analytical Equipment & Supplies
-
In Vitro Diagnostics
- Molecular Diagnostics & Genetic Testing
-
Biotechnology
- Nanotechnology, Chips, etc.
- Pharmacogenetics-Pharmacogenomics
Deal Status
- Final
Deal Type
-
Acquisition
- Full Acquisition
- Includes Contract
- Intra-Biotech Deal
- Payment Includes Cash
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com